A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Utilizing a filamentous fungus in the gut microbiome may provide a new strategy for treating metabolic dysfunction-associated ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

The researchers then investigated how the metabolisms of treated mice changed. They found that the effect was caused by ...

There's a lot going on in the teeming microbiomes of our guts, and we're regularly making new discoveries about these ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Researchers say semaglutide, the medication in Ozempic and Wegovy, may help reverse MASH, a progressive liver condition ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...